Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses

摘要: Background: In patients with well-differentiated (WD) neuroendocrine tumors (NET), long-acting octreotide (LAR), conventionally administered at a dose of 30 mg every 28 days, has well-documented anti-secretive but limited antiproliferative effects. Aim: The objective this study was to evaluate different schedule LAR treatment consistent shorter interval between administrations (21 days) in WD-NET progressive disease standard-dose interval. Subjects and methods: Twenty-eight followed for diagnosis therapy WDNET who had tumor progression during days were enrolled. Clinical, biological, response evaluated after 21 days. Time also compared Results: resulted complete partial control clinical symptoms 40% 60% cases, respectively. Circulating markers significantly decreased 30% cases. A stabilization obtained 93% 7%. median time longer by using the shortened administration as standard one (30 vs 9 months, p<0.0001). safe well tolerated. Conclusions: able re-institute symptoms, decrease level circulating increase previously escaping from treatment.